Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Net Income (2016 - 2025)

Historic Net Income for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to -$3.2 million.

  • Cytosorbents' Net Income fell 1452.31% to -$3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$16.4 million, marking a year-over-year increase of 1597.93%. This contributed to the annual value of -$20.7 million for FY2024, which is 2915.81% up from last year.
  • Latest data reveals that Cytosorbents reported Net Income of -$3.2 million as of Q3 2025, which was down 1452.31% from -$4.2 million recorded in Q2 2025.
  • In the past 5 years, Cytosorbents' Net Income ranged from a high of -$766126.0 in Q4 2022 and a low of -$12.2 million during Q3 2022
  • In the last 5 years, Cytosorbents' Net Income had a median value of -$6.2 million in 2023 and averaged -$6.1 million.
  • In the last 5 years, Cytosorbents' Net Income crashed by 127327.47% in 2021 and then skyrocketed by 9176.83% in 2022.
  • Quarter analysis of 5 years shows Cytosorbents' Net Income stood at -$9.3 million in 2021, then soared by 91.77% to -$766126.0 in 2022, then crashed by 758.12% to -$6.6 million in 2023, then fell by 15.1% to -$7.6 million in 2024, then skyrocketed by 58.11% to -$3.2 million in 2025.
  • Its Net Income stands at -$3.2 million for Q3 2025, versus -$4.2 million for Q2 2025 and -$1.5 million for Q1 2025.